Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychologic… Pending

2024-515147-32-02 Cocaine addiction 4
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age) Pending

2025-523711-11-00 Schizophrenia 5
The therapeutic potential of psilocybin in anorexia nervosa in young adults Pending

2024-515163-63-00 Anorexia Nervosa 4
Antidepressant effects of psilocybin without the psychedelic serotonin experience: A dimensional approach using functional neuroimaging. Pending

2025-521690-14-00 Major depressive disorder 4
Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia. Pending

2025-524794-16-00 Patients with major depressive episode and moderate to 6
Clinical trial to evaluate the effectiveness and efficiency of a pre-emptive pharmacogenetic strategy for antidepressant selection in patien… Pending

2025-522967-13-00 Depressive disorder 6
Efficacy of psilocybin and trazodone combination in treatment-resistant depression: a randomized controlled proof-of-concept study (PSILOTRA… Pending

2024-512911-34-00 Treatment-resistant depression 4
FELICITA - A proof of concept study: open label phase IIa trial evaluating the effect and safety of transplantation of fecal microbiota in c… Pending

2025-520539-17-00 Austistic spectrum disorder 4
TMSxDCS: Medicinal improvement of brain stimulation for depression. Pending

2025-521166-95-00 Major Depressive Disorder (MDD) 4
A randomized controlled trial of the effect of anesthetic dose during electroconvulsive therapy for major depression Pending

2024-519407-99-00 Major depressive disorder 6
An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending

2025-521757-16-00 Hallucinations and Delusions Associated with Alzheimer’ 4
OSU6162 as add-on in SSRI/SNRI-resistant depression (ODEN): a double-blind, placebo-controlled evaluation of efficacy and safety Pending

2024-513894-35-00 Depression 4
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavaila… Pending

2023-508981-13-00 Schizophrenia 2
Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial Pending

2025-520573-39-00 Ultra High Risk of psychosis and first episode psychos 6
Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5
Ketamine infusion for symptomatological improvement of severe borderline personality disorder: a pilot study Pending

2024-514361-19-00 borderline personality disorder 4
Etude de phase II évaluant la capacité d'un agoniste des récepteurs 5-HT4, le prucalopride (Resolor©), à accélérer l'efficacité thérapeutiqu… Pending

2025-521811-38-01 Dépression 4
A prospective, randomized, and controlled study comparing two treatment strategies (Dose REduction of Antipsychotics vs. Maintenance treatme… Pending

2023-509558-80-00 Patient with a diagnosis of schizophrenia spectrum diso 5
Effect of Minocycline on Inflammation in Depressed Patients Pending

2024-520076-10-01 Depression 4
Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (… Pending

2024-517963-21-00 Treatment Resistant Depression (TRD) 5
RESET-TRD; a Randomised trial on oral ESketamine compared to Electroconvulsive Therapy for patients with Treatment Resistant Depression Pending

2024-517485-42-00 Non-psychotic therapy resistant unipolar depression 5
Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial (PreKET) Pending

2025-521330-29-00 Major Depression Disorder (MDD) 4
A Phase 2 Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with Schizophrenia (STAR-1) Pending

2025-524058-32-00 Schizophrenia 4
Phase 3 Evaluation of KarXT and KarXT+KarX-EC in Schizophrenia and Autism-Related Irritability in Youth, respectively. Pending

2025-524062-16-00 Schizophrenia and Autism Spectrum Disorder (ASD) 5